CClinicalTrials.gg
RecruitingNCT07450898Updated Mar 5, 2026

Retrospective Analysis of Acute Pancreatitis After Percutaneous Mechanical Thrombectomy In Treatment Of Thrombotic Disorders

An observational study in Acute Pancreatitis (AP) and Thrombotic Disorders, sponsored by RenJi Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by RenJi Hospital · Observational

From the registry’s dates

  • Primary completion was expected by Mar 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Jan 2016; still recruiting 10 years 9 months later.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
10
Ages
18 Years and older
Sex
All
01

Study summary

Acute pancreatitis is a rare complication after percutaneous mechanical thrombectomy in treatment of thrombotic disorders. The objectives of this study include: (1) Determine the incidence and severity of acute pancreatitis after percutaneous mechanical thrombectomy; (2) Identify patient/procedural risk factors; (3) Evaluate clinical outcomes; (4) Develop a diagnosis and treatment pathway.

Read the detailed description

Percutaneous mechanical thrombectomy (PMT) has seen increasing utilization in the management of acute thrombotic events within both arterial and venous systems. The rheolytic thrombectomy such as AngioJet system employs hydrodynamic principles to disrupt and remove thrombus. The efficacy and safety have been demonstrated across various vascular diseases, including deep venous thrombosis (DVT), peripheral arterial occlusions, and dialysis access thrombosis, establishing PMT as a valuable minimally invasive therapeutic option. Acute pancreatitis is a serious inflammatory condition commonly associated with gallstones, alcohol consumption, hyperlipidemia, or metabolic disorders. Only isolated case reports have documented this complication following PMT. Despite the well-documented occurrence of other procedure-related adverse events, such as bradycardia, hemoglobinuria, and renal impairment, pancreatitis remains an exceptionally rare and under-recognized complication. The objectives of this study include: (1) Determine the incidence and severity of acute pancreatitis after percutaneous mechanical thrombectomy; (2) Identify patient/procedural risk factors; (3) Evaluate clinical outcomes; (4) Develop a diagnosis and treatment pathway.

02

Conditions studied

  • Acute Pancreatitis (AP)
  • Thrombotic Disorders

Browse trials for

Keywords

  • Thrombectomy
03

In context

Pancreatitis

752 studies on the registry are indexed under Pancreatitis; 181 are open to participants now.

This study's planned enrollment of 10 is below the median of 180 across 277 observational studies indexed under Pancreatitis.

Browse Pancreatitis studies →

Lead sponsor

RenJi Hospital is the lead sponsor of 535 studies on the registry; 244 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with acute pancreatitis after percutaneous mechanical thrombectomy for thrombotic disorders

Inclusion criteria

  • Patients over 18 years old;
  • Patients with thrombotic peripheral vascular diseases treated by percutaneous mechanical thrombectomy;
  • Patients developed acute pancreatitis within 14 days after percutaneous mechanical thrombectomy;
  • Patients with written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Patients with acute pancreatitis attributed to other confirmed causes;
  • Patients unable or unwilling to participate in the study.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
10 participants (estimated)
Patient registry
No

Groups and cohorts

  • Acute pancreatitis after percutaneous mechanical thrombectomy group

    Patients were diagnosed with acute pancreatitis after percutaneous mechanical thrombectomy in treatment of thrombotic disorders.

06

What researchers measure

Primary outcomes

  1. Incidence of acute pancreatitis

    The incidence of acute pancreatitis within 14 days after mechanical thrombectomy for peripheral thromboembolic disease.

    Time frame: Within 14 days

Secondary outcomes

  1. Incidence of acute severe pancreatitis

    The incidence of acute severe pancreatitis within 14 days after mechanical thrombectomy for peripheral thromboembolic disease.

    Time frame: Within 14 days

Other outcomes

  1. Admission to intensive care unit rate

    Safety outcomes: Admission to intensive care unit rate within 60 days after mechanical thrombectomy for peripheral thromboembolic disease

    Time frame: Within 60 days

  2. All-cause mortality rate

    Safety outcomes: All-cause mortality rate within 60 days after mechanical thrombectomy for peripheral thromboembolic disease during hospitalization

    Time frame: within 60 days

07

Study locations

1 of 1 sites recruiting
  • Renji Hospital
    Shanghai, Shanghai Municipality 200217, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07450898
Lead sponsor
RenJi Hospital
Responsible party
Sponsor
First posted
Mar 5, 2026
Start date
Jan 1, 2016
Primary completion
Mar 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 5, 2026

Study contacts

Qihong Ni
Contact
niqihong1989@163.com
15801900772
Qihong Ni
principal investigator · Department of Vascular Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion